At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 48 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
In Brief
A Phase 4 clinical trial evaluating Apixaban and Warfarin for Antiphospholipid Syndrome and Thrombosis. Completed, enrolled 48 participants across 2 sites.
Detailed Summary
This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAntiphospholipid Syndrome, Thrombosis
CountriesUnited States
CollaboratorsBristol-Myers Squibb, University of Utah
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartDec 2014
Primary CompletionApr 2020
Study CompletionMar 2022
TodayJul 2026
First PostedNov 20, 2014
Enrollment StartDec 10, 2014
Primary CompletionApr 1, 2020
Study CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.6 years ago
Interventions
Apixabandrug
Warfarindrug